Invest in Cancer Stocks PDF Download

Author: Eric Shea Broadus
Publisher: WestBow Press
ISBN: 1664287892
Category : Business & Economics
Languages : en
Pages : 119

View

Book Description
If you like investing in stocks and hate cancer, then why not build wealth by investing in companies dedicated to fighting the disease? Eric Shea Broadus, a cancer survivor and the founder of an investment advisory firm, draws on his decades of experience in the financial arena to help investors make money while supporting a great cause. Learn how to: • determine who to consult when making investment decisions; • identify publicly traded companies that are waging war against cancer; • evaluate investments based on key metrics; • establish and track investment goals. Throughout the book, the author highlights why supporting companies that are seeking to fight, treat, and cure cancer is so important, as well as the lessons he learned battling cancer. Companies dedicated to fighting cancer and bolstering the immune system are making a significant difference for millions of current and future cancer patients and have produced wonderful financial returns for many investment portfolios. Learn how to build a profitable portfolio consisting of oncology stocks, health insurance stocks, and real estate investment trusts related to cancer treatment with this guide.

Author: Joe Duarte
Publisher: Prima Lifestyles
ISBN:
Category : Business & Economics
Languages : en
Pages : 424

View

Book Description
Medical biotechnology is a multibillion dollar global industry, and is growing rapidly. Breakout companies worldwide present highly profitable investment opportunities, but many investors avoid the sector because the science is difficult to understand and the opportunities easy to miss. Where can the layperson find reliable, fundamental information about biotechnology in order to make informed investment decisions?In Successful Biotech Investing, market expert and physician Joe Duarte, M.D., makes investing in biotech companies -- and understanding the basic science -- easy. He combines his professional medical insight and extensive financial experience to help investors easily master how to: * Interpret the science to make informed investment decisions* Analyze biotech companies for research, patents, and growth potential* Pick biotech mutual funds and indexes for maximum profit* Identify related opportunities in pharmaceutical and health-care companies* Understand the impact of the FDA and international regulations* And much moreWritten for smart investors who want to learn more about biotech and its opportun

Author: Bhavneesh Sharma, M.d.
Publisher: CreateSpace
ISBN: 9781517247997
Category :
Languages : en
Pages : 126

View

Book Description
The revolution in cancer treatment, especially immune-therapy (using the body's own immune system to fight cancer cells) is once in the lifetime opportunity for investors to make a fortune. This book discusses some promising cancer therapy companies with significant upside potential in stock price.

Author: Standard and Poor's Corporation
Publisher: McGraw Hill Professional
ISBN: 9780071384131
Category : Biotechnology industries
Languages : en
Pages : 336

View

Book Description
Standard and Poor's has been the leading brand in financial information and analysis around the world. Brokers, investment bankers, and other Wall Street professionals have relied upon S&P's unparalleled financial analysis for over 140 years. Their stock reports and ratings are among the most-respected in the industry. Now S&P's celebrated stock reports are collected for the top-rated stocks in the S&P 1500 composite index for each of today's five hottest stock sectors. Finance; Technology; Health Care, Pharmaceutical and Biotechnology; Energy; Communications and Telecom; The industries in these sectors include some of the fastest growing stocks around, and each of them include stocks assigned the prestigious 5-Star rating by S&P's top analysts. 65 percent of the 5-Star rankings allotted to stocks in S&P's 1500 composite index were assigned to stocks in one these 5 sectors! Included in each book are S&P's exclusive stock reports for the top-rated companies in each industry in the sector. Each book will also contain S&P analysts' valuable analysis of the sector as a whole and exclusive advice on how to evaluate stocks in each industry in the sector.

Author: Leo Gough
Publisher: John Wiley & Sons
ISBN:
Category : Business & Economics
Languages : en
Pages : 268

View

Book Description
Leading investment author and journalist Leo Gough provides them with a rare insider's look at the biotech industries based on extensive interviews with industry analysts, CEOs, and leading scientists at top biotech firms, including Merck & Co., Eli Lilly & Co., Amgen Ltd., SmithKline Beecham, Inc., Genzyme Corp., Monsanto, and others."--BOOK JACKET.

Author: Larry Waschka
Publisher: August House Publishers
ISBN: 9780970757807
Category : Business & Economics
Languages : en
Pages : 196

View

Book Description
During the 1990s, stocks like Cisco, AOL, Dell and Qualcomm made many people multi-millionaires in less than a decade. Now most people think the Internet Revolution is over. They are dead wrong. You Ain't Seen Anything Yet We are only at the very beginning of a decade of revolutionary change and revolutionary stock market returns. Your key to building wealth in this decade is all about investing in the stocks that are providing the key platform or infrastructure within the fastest growing industries in the world. This book narrows down your search and identifies the economic revolutions that are changing the world, the industries that they spawn and the stocks that are leading the way in each industry.In this book you will find: -- The Secret to Successful Investing -- Ten Stocks that Could Change the World -- Ten Stocks that Are Changing the World -- How to Buy These Stocks

Author: Boris Bogdan
Publisher: Springer Science & Business Media
ISBN: 3642108202
Category : Business & Economics
Languages : en
Pages : 370

View

Book Description
Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some claim it to be an art. In the following chapters we will provide the user with a concise val- tion manual, providing transparency and practical insight for all dealing with valuation in life sciences: project and portfolio managers, licensing executives, business developers, technology transfer managers, entrep- neurs, investors, and analysts. The purpose of the book is to explain how to apply discounted cash flow and real options valuation to life sciences p- jects, i.e. to license contracts, patents, and firms. We explain the fun- mentals and the pitfalls with case studies so that the reader is capable of performing the valuations on his own and repeat the theory in the exercises and case studies. The book is structured in five parts: In the first part, the introduction, we discuss the role of the players in the life sciences industry and their p- ticular interests. We describe why valuation is important to them, where they need it, and the current problems to it. The second part deals with the input parameters required for valuation in life sciences, i.e. success rates, costs, peak sales, and timelines.

Author: Les Funtleyder
Publisher: McGraw Hill Professional
ISBN: 0071642951
Category : Business & Economics
Languages : en
Pages : 304

View

Book Description
Is your portfolio in peak health? Ranking among the world's largest markets, the $2.5 trillion health care industry is growing at an unprecedented rate. According to Miller Tabak + Co.'s health care strategist Les Funtleyder, major structural renovations to the system are imminent. “Health care is entering an era of reform,” Funtleyder writes, “and with reform comes change and the opportunity for investment gain.” Health-Care Investing provides a thorough explanation of how the industry's mammoth size and complexity can be worked to your advantage and why health care is more resistant to changes in economic cycles than other markets. Funtleyder gives you a comprehensive overview of the industry, from both macro and micro points of view, so you can make informed decisions regarding your investments. You'll find critical information concerning The natural inelasticity of health care and how to profit from it How to take advantage of the market's complexities and inefficiencies Issues and policy changes you need to know The social responsibility aspect of investing in health care Why this market is essential for diversified portfolios In Health-Care Investing, Funtleyder provides the tools you need to dig up the richest opportunities possible and build them into your investment strategy. You'll get a detailed look at traditional market patterns and the events that have shaped--and will continue to shape--the industry. Then you'll find specific strategies you can use to maximize your profits, whether you invest in pharma, biotech, managed services, or a combination of them. This informative and practical guide also includes a list of questions you can use as an investment “template,” which will help guide your decision-making process. With Health Care Investing, you'll be armed with the know-how to make the right decisions today in order to fully capitalize on events of the future.

Author: Alex Prud'homme
Publisher: Harper Collins
ISBN: 0061865621
Category : Business & Economics
Languages : en
Pages : 438

View

Book Description
"It began with a promising cancer drug, the brainchild of a gifted researcher, and grew into an insider trading scandal that ensnared one of America's most successful women. The story of ImClone Systems and its "miracle" cancer drug, Erbitux, is the quintessential business saga of the late 1990s. It's the story of big money and cutting-edgescience, celebrity, greed, and slipshod business practices; the story of biotech hype and hope and every kind of excess. At the center of it all stands a single, enigmatic figure named Sam Waksal. A brilliant, mercurial, and desperate-to-be-liked entrepreneur, Waksal was addicted to the trappings of wealth and fame that accrued to a darling of the stock market and the overheated atmosphere of biotech IPOs. At the height of his stardom, Waksal hobnobbed with Martha Stewart in New York and Carl Icahn in the Hamptons, hosted parties at his fabulous art-filled loft, and was a fixture in the gossip columns. He promised that Erbitux would "change oncology," and would soon be making $1 billion a year. But as Waksal partied late into the night, desperate cancer patients languished, waiting for his drug to come to market. When the FDA withheld approval of Erbitux, the charming scientist who had always stayed just one step ahead of bankruptcy panicked and desperately tried to cash in his stock before the bad news hit Wall Street. Waksal is now in jail, the first of the Enron-era white-collar criminals to be sentenced. Yet his cancer drug has proved more durable than his evanescent profits. Erbitux remains promising, the leading example of a new way to fight cancer, and patients and investors hope it will be available soon.

Author: Gene G. Marcial
Publisher: FT Press
ISBN: 0132703432
Category :
Languages : en
Pages : 224

View

Book Description
“Gene Marcial provides iconoclastic insights into the art of successful investing while exploding the mythology of the conventional wisdom. His 7 Commandments of Stock Investing is scintillating reading for both individual and institutional investors who seek an advantage in their moneymaking endeavors.” --Scott Black, President of Delphi Management Inc. and a member of the Barron’s Roundtable “It is well understood that trading in the stock market is full of risks. But if you are ready to take the plunge, I guarantee that there will be a time when being familiar with Gene Marcial’s 7 Commandments of Stock Investing will be extremely important. Over the years, I have followed many of the same commandments.” --Carl Icahn, Chairman, Icahn Associates “This book begins with one of the wisest investment observations I’ve ever encountered: ‘There are plenty of ways to make money in the stock market, but clinging to mainstream thinking or so-called conventional wisdom is not one of them.’ The author’s discussion on avoiding the diversification trap is alone worth many times the price of this book.” --Bernie Schaeffer, Chairman, Schaeffer’s Investment Research, Inc., www.SchaeffersResearch.com “Gene Marcial has been guiding literally millions of investors to better financial performance over his more than 30 years as a leading financial journalist. He consistently has demonstrated a rare instinct for knowing when to follow a trend and when to think like a contrarian. In today’s turbulent times, his new book, 7 Commandments of Stock Investing, is essential reading for all investors and could well add precious percentage points to the performance of any who take his words to heart.” --Stephen Leeb, President, Leeb Capital Management Inc. Every week, the investment world turns to Gene Marcial’s BusinessWeek column. Here’s why: Marcial knows how to pick winners. Apple at 15. US Steel at 19. But Marcial’s track record isn’t limited to just one or two picks. In fact, recent analysis reveals that he’s beaten the indexes for a full decade. You can’t get results like that following the “conventional wisdom”! You need to know what Gene Marcial has learned about stock investing--and this book will tell you. Marcial has distilled 35 years of experience into seven powerful, counterintuitive “commandments”: rules that are simple and practical enough for every investor to profit from. Marcial reveals why diversification is not an optimal investment strategy...why you need to focus on finding big winners, and how you can...how to profit from panic, and how to lock in your profits when everyone else is “fat and happy.” Along the way, he opens up the secret, mysterious world of corporate and market insiders--showing how to track them down, emulate their approaches, and profit from their lucrative strategies. Be prepared to profit from panic Plot a clear strategy to seize opportunities during a macro-market panic Learn how to “buy the losers” Finding tomorrow’s big winners in today’s bargain bin Profit from the unknown Finding investments that are undervalued because investors don’t understand them The “sweet seven”: specific stock picks for the next seven years What to buy right now--and hold for the long term